Over 1,000 Chemotherapy Protocols And Counting

Phase III, randomized, controlled, multicenter, open-label trial (İMbrave050) HCC pts at high risk of recurrence following resection or ablation. Atezolizumab + Bevacizumab q21 (n

15 Mar

Mantle cell lymphoma

New Drug: Pirtobrutinib in Mantle Cell Lymphoma

Open-label, multicenter, single-arm trial (BRUIN) Mantle cell lymphoma previously treated with a BTK inhibitor Pirtobrutinib (n=120)

20 Aug

Diffuse Large B Cell Lymphoma

New Drug: Glofitamab in Large B-Cell Lymphoma

Phase I-II, open-label, multicenter study Relapse or refractory large cell lymphoma Glofitamab (n=132)

20 May

Skin Cancer (Other than Melanoma)

New Drug: Retifanlimab in Advanced Merkel Cell Carcinoma

Open-label, multicenter, single-arm, phase 2 study Treatment naïve metastatic or recurrent locally advanced MCC Retifanlimab q28 (n=65)

20 May

Breast Cancer

New Reference: Trastuzumab Deruxtecan for her2-Positive Breast Cancer

Phase III, randomized, controlled, multicenter, open-label trial (DESTINY-Breast-02) HER2-positive, previously received trastuzumab-emtansine, unresectable or metastatic breast can

24 Jun

Soft Tissue Sarcoma

New Protocol: Nivolumab and Trabectedin in Advanced Soft Tissue Sarcoma

Prospective, explorative, two-group, non-randomized, phase II trial (NITraSarc) Advanced, previously treated lipo-leiomyosarcoma (Group A: GA) (n=43) and non-L-sarcomas (Group B:

20 Sep

Mantle cell lymphoma

New Protocol: Ibrutinib with Rituximab and Bendamustine for Mantle Cell Lymphoma

International, randomized, double-blind, phase 3 trial (SHINE) 65 years of age or older mantle cell lymphoma Untreated, stage II to IV disease Ibrutinib (N:261) or placebo (N:262),

14 Apr

Melanoma

New Indication: Perioperative Pembrolizumab in Melanoma

Open-label, phase 2 study Treatment naïve resectable sage IIIB-IVC metastatic melanoma (cutaneous, acral, or mucosal) Pembrolizumab: Neoadjuvant-adjuvant (n=154) vs. Adjuvant (n=1

20 Sep

Non-Small Cell Lung Cancer

New Indication: Neoadjuvant Nivolumab for NSCLC

Open-label, phase 3 trial Stage IB to IIIA resectable NSCLC Three cycles neoadjuvant treatment Nivolumab plus platinum-based chemotherapy (n=176) or platinum-based chemotherapy (n=

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries